PMID-41476424 – Injectable Peptide Therapy Primer for Sports Medicine
Mayfield CK, et al. Injectable peptide therapy: a primer for the sports medicine clinician. Am J Sports Med. 2026. DOI: 10.1177/03635465251357593.
Quick Reference
| Property | Value |
|---|---|
| PMID | 41476424 |
| DOI | 10.1177/03635465251357593 |
| Year | 2026 |
| Journal | American Journal of Sports Medicine |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | Review of injectable peptide therapies relevant to sports medicine |
| Peptide(s) Studied | CJC-1295 NO DAC, Ipamorelin |
Key Findings
- Clinical primer specifically written for sports medicine physicians on injectable peptide therapies
- CJC-1295 + ipamorelin combination reviewed as the most commonly used GH secretagogue protocol in clinical practice
- In murine models, the CJC-1295/ipamorelin combination showed improved maximum tetanic tension, suggesting enhanced muscle performance
- The review notes a significant lack of human orthopaedic validation studies for these peptides
- Provides practical guidance on dosing protocols, monitoring, and patient selection for sports medicine contexts
- Emphasizes the need for rigorous clinical trials before these peptides can be recommended as standard of care
Study Design
Narrative review synthesizing the available preclinical and clinical literature on injectable peptides used in sports medicine. Evaluated evidence for mechanism of action, efficacy, safety, and regulatory status. Focused on practical clinical considerations for sports medicine practitioners including patient selection, dosing, monitoring, and risk-benefit assessment.
Limitations
- Narrative review with inherent selection bias
- Limited high-quality human evidence available to review for most peptides discussed
- The murine tetanic tension data for CJC/ipamorelin has limited translatability to human athletic performance
- No systematic quality assessment of included studies
- Potential for author bias toward or against peptide therapy adoption
Clinical Relevance
This review from a leading sports medicine journal (AJSM) represents growing mainstream medical acceptance of peptide therapies as a legitimate clinical tool. For practitioners already using CJC-1295 and ipamorelin, it provides peer-reviewed support for their clinical rationale while appropriately noting evidence gaps. The publication in AJSM also helps legitimize peptide therapy discussions with patients, insurers, and medical boards. The explicit call for human orthopaedic trials identifies the key research gap that needs to be filled.
Related
#research #narrative-review #CJC-1295 #ipamorelin #evidence-level-V